Scinai Immunotherapeutics Ltd. (FRA:2F5)

Market Cap	2.86M +0.4%
Revenue (ttm)	976.67K +303.9%
Net Income	295.47K
EPS	0.22
Shares Out	n/a
PE Ratio	9.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.8300
Previous Close	0.8800
Day's Range	0.8250 - 0.8300
52-Week Range	0.5350 - 4.9800
Beta	n/a
RSI	52.64
Earnings Date	Mar 27, 2026

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies....

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2F5

Financial Performance

Financial numbers in USD